Millipore Demonstrates Leadership in Sustainability by Reducing Carbon Footprint 14 Percent

April 22, 2009

BILLERICA, Mass.--(BUSINESS WIRE)--Millipore Corporation (NYSE: MIL), a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today announced that it has reduced its carbon emissions 14 percent below its 2006 baseline. Most of the reductions were achieved since the company announced its global Sustainability Initiative in May 2008.

Millipore's Sustainability Initiative is an ambitious effort aimed at reducing the company's environmental impacts and carbon footprint by 20 percent over five years. This significant reduction is expected to be achieved through a range of programs focused on reducing the company's consumption of non-renewable resources, eliminating waste, and adopting behavioral changes that support long-term environmental sustainability. Many of these programs are aimed at reducing Millipore's contribution to greenhouse gas emissions, a key factor in global climate change.

"I am proud of the significant progress we have made in reducing our carbon footprint over the past twelve months," said Martin Madaus, President and CEO of Millipore Corporation. "The issue of global economic climate change is an important one for all business leaders, and we are demonstrating how taking a targeted approach can drive results quickly. Globally, we now purchase 10 percent of our energy from renewable sources, and we will be stepping up our efforts to further reduce our environmental impactsâ€"through our products and packaging, operational improvements, and behavioral changes."

In conjunction with Earth Day, Millipore also issued its first annual Sustainability Report, which describes other major achievements, as well as priorities, in its global sustainability efforts. The company's accomplishments include savings of 5.1 million kilowatt hours of energy through efficiency measures; switching over its U.S. fleet to include 30 percent hybrid vehicles and initiating an employee hybrid vehicle incentive program; and introducing its first bioplastic product, EcoStand(TM). The Sustainability Report aligns with the Global Reporting Initiative's (GRI) G3 Sustainability Reporting Guidelines.

Ongoing priorities for Millipore include, where practicable, the incorporation of "green" building practices in renovation and construction projects, reducing water use through process engineering improvements, and using Design for Environment tools in its products and packaging.

"Our vision is to establish Millipore as a role model for sustainability leadership," said David Newman, Director of Sustainability at Millipore. "We are working hard to achieve leading-edge product stewardship, state-of-the-art packaging options, and a culture of sustainability. We have ambitious goals, but by taking a focused approach to our sustainability activities we are confident they can be achieved."

Millipore has become a partner in Climate Leaders, a voluntary partnership between industry and the U.S. Environmental Protection Agency (EPA) to develop greenhouse gas-reduction strategies. Recently, the company also joined the EPA's Green Power Partnership and has purchased renewable energy for five manufacturing facilities.

For more information about Millipore's Sustainability Initiative, visit the Sustainability section of the company's website:

About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit

Research. Development. Production.

Safe Harbor Statement
Certain of the matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers' manufacturing design phase for a particular drug; delay, suspension or termination of a customer's volume production; fluctuations in the timing of customers' orders; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; risks relating to our concentration of principal manufacturing operations; the inability to successfully integrate acquired businesses; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.